Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Teva’s New Treatment for Huntington’s Disease Approved by FDA

XTALKS VITALS NEWS

According to a press release issued by the company, it’s been nearly ten years since a new drug for chorea associated with Huntington’s disease has been approved by the regulator.

Share this!

April 6, 2017 | by Sarah Hand, M.Sc.

Teva Pharmaceuticals’ Huntington’s Disease drug, Austedo (deutetrabenazine), has been approved by the FDA for the treatment of involuntary movements associated with the disorder, known as chorea. According to a press release issued by the company, it’s been nearly ten years since a new drug for chorea associated with Huntington’s disease has been approved by the regulator.

“Chorea is a major symptom for many living with Huntington disease. It impacts patients’ functionality and activities of daily living, and there have been limited treatment options for these patients,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva. “Based on the results demonstrated in the clinical development program which supported the approval of Austedo and our ongoing commitment to patients, we feel uniquely positioned to bring this treatment option forward.”

Huntington’s disease is a rare and often fatal neurodegenerative disorder which affects over 35,000 patients in the US. Around 90 percent of these patients experience symptoms of chorea, including sudden and involuntary twisting and writhing movements.



The results from two Phase III clinical trials – FIRST-HD and ARC-HD – were used to support the FDA’s decision to approve Austedo. The FIRST-HD study provided evidence that Austedo was able to reduce chorea in patients, compared to a placebo. Patients who were taking tetrabenazine, the only other FDA approved treatment for chorea, were able to switch to Austedo without losing symptom control, in the ARC-HD clinical trial.

“Chorea associated with Huntington’s disease has a significant impact on those living with the disease and their families,” said Louise Vetter, CEO of the Huntington’s Disease Society of America. “The FDA’s approval of Austedo represents an important new treatment option for people with HD and highlights the need for more therapeutic resources for this underserved patient community.”

Austedo is a small molecule drug designed to regulate neuronal levels of dopamine. The drug does carry a warning that Austedo can increase the risk of depression and suicidal ideation in patients with Huntington’s disease, which could limit its use.

Teva added Austedo to their portfolio after the 2015 acquisition of Auspex Pharmaceuticals. The FDA granted Orphan Drug Designation to Austedo in late 2014.


Keywords:  FDA, Huntington's Disease, Dopamine


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.